Amgen Says AstraZeneca Files Biologics License Application for Severe Asthma Drug Tezepelumab
09:42 AM EDT, 05/10/2021 (MT Newswires) -- Amgen (AMGN) said Monday that AstraZeneca (AZN) has submitted a biologics license application to the US Food and Drug Administration for potential severe asthma treatment tezepelumab.
In a phase 3 trial, the drug showed a "statistically significant and clinically meaningful" reduction in annualized asthma exacerbation rate compared with placebo.
The drug is being developed under a collaboration agreement first signed between the parties in 2012.
AMGN and AZN shares were over 1% higher in early Monday trade.
Price: 256.17, Change: +1.96, Percent Change: +0.77